000			01910nam a22002657a 4500
001			20240809174659.0
003			20240809174659.0
005			20240809175115.0
008			240809b |||||||| |||| 00| 0 eng d
020			_a978-3-319-43896-2
020			_a978-3-319-43894-8
022			_a 0927-3042
022			_a 2509-8497
040			_cddc
041			_aEnglish
100			_eJune M. McKoy
245			_a Cancer Policy _bPharmaceutical Safety
260			_aFeinberg School of Medicine Northwestern University Chicago, IL, USA : _bSpringer Nature Switzerland AG : _c2019
300			_a129 Pages
490			_ahttps://doi.org/10.1007/978-3-319-43896-2
520			_aCancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
600			_xMedical / Clinical Medicine, Medical / Oncology / General, Medical / Pharmacology, Oncology, Pharmacovigilance, Cancer -- Treatment, Drugs -- Safety measures, Medical policy, Pharmaceutical industry, Pharmaceutical policy, Pharmacy
700			_eDennis P. West
942			_2ddc _cEB _n0
999			_c28220 _d28220